secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vivos Therapeutics, Inc. (VVOS)
CIK:        0001716166
Form:       8-K
Filed at:   2025-09-18T23:59:59+00:00
Accession:  0001493152-25-013953
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vivos DNA appliance shows 77% of pediatric OSA patients achieve ≥50% severity reduction in peer-reviewed trial
--------------------------------------------------------------------------------

- 77% of participants had ≥50% reduction in OSA severity; 93% with severe OSA reached that threshold.
- 17% of children achieved complete resolution of OSA; airway volume increased 67.8% on average.
- Pediatric Sleep Questionnaire scores improved 31% – statistically significant.
- Data published in European Journal of Pediatrics; first multicenter trial for DNA appliance in pediatric OSA.
- Study provides evidence for non-surgical alternative to adenotonsillectomy, which is only 20–40% effective.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1716166/000149315225013953/0001493152-25-013953-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1716166/000149315225013953/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-013953

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer